Bio-Thera Solutions (688177.SH) signed a commercialization agreement with Avalon Pharma for BAT3306 (Paboli Zhu Monoclonal Antibody) injection.

Bio-Thera Solutions (688177.SH) announced that on February 3, 2026, the company signed an authorization and commercialization agreement with Avalon Pharma. According to the agreement, Bio-Thera Solutions will grant Avalon exclusive commercialization rights for the company's BAT3306 (PB006 monoclonal antibody) injection in the markets of Saudi Arabia, the Middle East, and North Africa, in exchange for a payment. Bio-Thera Solutions will receive a total amount of up to $7 million as an upfront payment and milestone payments, including a $2 million upfront payment, cumulative milestone payments not exceeding $5 million, and a double-digit percentage of net sales as revenue share. BAT3306 (PB006 monoclonal antibody) is developed by Bio-Thera Solutions based on the biosimilar guidelines of the National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA). PB006 monoclonal antibody is a humanized monoclonal antibody drug belonging to the immune checkpoint inhibitor class. Avalon is a leading regional healthcare company headquartered in Riyadh, Saudi Arabia. The signing of this agreement aims to quickly convert the company's research and development achievements into company benefits through commercial cooperation and licensing. The cooperation between the company and Avalon will organically combine international advanced research and development, production quality control, technology enhancement, clinical applications, and commercial promotion, creating favorable conditions for the company's future development and greatly enhancing the company's core competitiveness. The successful implementation of the agreement is expected to have a positive impact on the company's future business performance.